Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Maturitas

• Publication date

  2004-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.MATURITAS.2004.01.012PMID 15172082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein

  2001cited by this paper
• Randomized Comparison of Intranasal and Transdermal Estradiol

  2000cited by this paper
• Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.

  2000cited by this paper
• Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year.

  2000cited by this paper
• Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.

  1999cited by this paper
• A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women

  1999cited by this paper
• Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations

  1999cited by this paper
• Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.

  1999cited by this paper
• Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response study

  1999cited by this paper
• Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.

  1999cited by this paper
• A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss

  1999cited by this paper
• Matrix Delivery Transdermal 17β-Estradiol for the Prevention of Bone Loss in Postmenopausal Women

  1999cited by this paper
• A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.

  1999cited by this paper
• Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

  1997cited by this paper
• Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

  1996cited by this paper
• Prospective study of exogenous hormones and risk of pulmonary embolism in women.

  1996cited by this paper
• Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.

  1996cited by this paper
• Risk of venous thromboembolism in users of hormone replacement therapy.

  1996cited by this paper
• The menopause and osteoporosis.

  1996cited by this paper
• Perspectives: How many women have osteoporosis now?

  1995cited by this paper
• The Effects of Transdermal Estradiol and Oral Conjugated Estrogens on Haemostasis Variables

  1994cited by this paper
• The effect of postmenopausal estrogen therapy on bone density in elderly women.

  1993cited by this paper
• Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial.

  1993cited by this paper
• Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study.

  1993cited by this paper
• Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women.

  1992cited by this paper
• Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal women

  1992cited by this paper
• Low-Dosage Micronized 17β-Estradiol Prevents Bone Loss in Postmenopausal Women

  1992cited by this paper

• Local estradiol deposition in a rat rotator cuff repair model: proof of concept

  2025cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper
• Effects of Drugs on Bone Quality

  2016cites this paper
• Flaxseed enhances the beneficial effect of low-dose estrogen therapy at reducing bone turnover and preserving bone microarchitecture in ovariectomized rats.

  2014cites this paper
• Flaxseed and Lower-dose Estrogen: Studies on Their Protective Actions and Mechanisms in Bone Using the Ovariectomized Rat Model

  2012cites this paper
• Regulation of bone quality and calcium absorption in obesity and during caloric restriction in women

  2011cites this paper
• The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women

  2009cites this paper
• Bone turnover markers: an appreciation of the contribution of Dr. P.D. Delmas.

  2008cites this paper
• Drug delivery systems for hormone therapy.

  2006cites this paper
• Effects of intranasal 17&bgr;-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women

  2006cites this paper
• Pharmacology of estrogens and progestogens: influence of different routes of administration

  2005cites this paper
• Pulsed estradiol exposure has a limited ability to induce uterine proliferation in ovariectomised female Wistar rats.

  2005cites this paper